SOUTH SAN FRANCISCO, Calif., May 24, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in three upcoming investor conferences. Any available webcasts will be posted to the Company’s…Read More
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences Allogene Therapeutics NASDAQALLO
